ST. PAUL, Minn. – “When we first ran I stressed the importance of changing the way we do politics,” Senator Matt Little (DFL-Lakeville) replied when asked about his bill hearing, “and today we were able to break through the partisanship to stand up for Minnesotans with diabetes.”
Minnesota diabetics would no longer risk losing coverage of their brand of insulin, equipment, or supplies thanks to legislation presented by Senator Little in the Senate Commerce and Consumer Protection Finance and Policy Committee Tuesday.
“This bill recognizes a major problem that faces thousands of Minnesotans, and would enact policy that provides stability, confidence, and assurance for people that the medications they need to live are available to them,” said Senator Little.
The legislation, SF 365, would require health plan companies to disclose the brand or brands of insulin and equipment and supplies they cover, and prohibits the removal from coverage of any particular brand of insulin, equipment, or supplies described during an enrollee’s contract year. The only acceptable reason for removing a brand would be if it is deemed unsafe or has been withdrawn from the market by the product manufacturer.
“This legislation is a common sense, bipartisan proposal that simply asks insurers to hold up to their end of the contract for a one-year period” said Senator Little. “I’m proud that my colleagues on the committee on both sides of the aisle recognize the need for getting this done and putting people first.”
Senator Little’s bill has bipartisan support in the Senate, with an equal number of Democrats and Republicans as co-authors. The bill is co-authored by Senators Matt Klein (DFL-Mendota Heights), Jim Abeler (GOP-Anoka), Scott Jensen (GOP-Chaska) and Melisa Franzen (DFL-Edina).